Complete Tumor Response with Afatinib 20 mg Daily in EGFRMutated Non-small Cell Lung Cancer: A Case...
Complete Tumor Response with Afatinib 20 mg Daily in EGFRMutated Non-small Cell Lung Cancer: A Case Report
About this item
Full title
Author / Creator
Publisher
Auckland: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Auckland: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
Published online: 15 March 2017 © Springer International Publishing Switzerland 2017 Abstract Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is efficacious as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). According to labeling recommendations, the starting do...
Alternative Titles
Full title
Complete Tumor Response with Afatinib 20 mg Daily in EGFRMutated Non-small Cell Lung Cancer: A Case Report
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1973390729
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1973390729
Other Identifiers
ISSN
1173-2563
E-ISSN
1179-1918
DOI
10.1007/s40261-017-0515-2
